A prescription-only intravenous Alzheimer’s treatment has launched in India at Rs 91,688 for a 350 mg vial. The monthly therapy can be given for up to 18 months, making the total cost potentially steep for many patients. The drug targets the underlying disease process linked to amyloid plaque buildup and neurofibrillary tangles in the brain.
India’s cancer care is shifting as cheaper immunotherapy drugs developed in China arrive through Indian partnerships. Oncologists say these options are expanding access for patients who cannot afford pricier Western medicines. The result, doctors claim, is less financial strain and fewer cases where cancer treatment drives families into severe debt, alongside improving affordability of sustained care.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
PFRDA has launched NPS Swasthya, a pilot scheme designed to help subscribers earmark money for healthcare while still planning for retirement. Users can contribute any amount, withdraw up to 25% specifically for medical needs, and exit fully for critical treatments. The model aims to blend pension discipline with timely access to healthcare funds.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
